Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IN-2502
- Development stage
- Preclinical
- Lead developer
- Indivumed
01
Overview
IN-2502 is a preclinical biologic drug candidate being developed by Indivumed for the treatment of colorectal cancer (CRC). The drug was identified through Indivumed's proprietary multi-omics platform, which analyzes high-quality patient biospecimens to discover novel therapeutic targets. As of September 2025, IN-2502 is in the 'Hit to Lead' stage of development. While the specific molecular target and mechanism of action have not been publicly disclosed by the company, the program is part of a specialized pipeline aimed at addressing the molecular drivers of CRC and potentially other solid tumors.
Beyond the preview
Go deeper on IN-2502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN-2502.